Novartis shared results from a pooled analysis of four Phase 3 clinical trials demonstrating patients with moderate to severe plaque psoriasis (PsO) treated with Cosentyx (secukinumab) 300mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnaire as early as Week 4 when compared to placebo in patients who reported problems at baseline. The results were presented at the 15^th Annual Maui Derm for Dermatologists 2019.

"Moderate to severe plaque psoriasis can impact every aspect of a person's life," stated Steven R. Feldman, MD, PhD, Wake Forest School of Medicine. "These findings suggest that helping patients feel better through improved quality of life and ability to function should be a goal as important as skin clearance in psoriasis management."

The pooled analysis of the ERASURE, FIXTURE, FEATURE, and JUNCTURE trials included patients with moderate to severe plaque psoriasis who were randomized to receive placebo or Cosentyx 300mg and who reported problems with mobility, self-care, or usual activities (e.g., work, study, housework, family or leisure activities) at baseline, as recorded by the EQ-5D questionnaire. The percentages of patients reporting problems in the EQ-5D-3L mobility, self-care, or usual activities domains were compared at weeks 4, 8, and 12 between patients receiving placebo (n=282) and Cosentyx 300 mg (n=309).

• Change in Mobility: The percentage of patients reporting no problems in mobility at Week 4 was higher with Cosentyx 300 mg compared with placebo (60.7% vs 38.5%); similar trends were observed at Weeks 8 (73.6% vs 48.1%) and 12 (71.4% vs 46.6%).
• Change in Self Care: The percentage of patients reporting no problems in self-care at Week 4 was higher with Cosentyx 300 mg compared with placebo (71.4% vs 40.9%); similar trends were observed at Weeks 8 (79.2% vs 42.3%) and 12 (87.1% vs 43.0%).
• Change in Usual Activities: The percentage of patients reporting no problems in usual activities at Week 4 was twice higher with Cosentyx 300 mg compared with placebo (63.8% vs 31.1%); similar trends were observed at Weeks 8 (74.4% vs 35.7%) and 12 (82.7% vs 42.6%).